
1. chemmedchem. 2008 nov;3(11):1756-62. doi: 10.1002/cmdc.200800183.

optimization 5-aryloxyimidazole non-nucleoside reverse transcriptase
inhibitors.

jones lh(1), allan g, corbau r, hay d, middleton ds, mowbray ce, newman sd,
perros m, randall a, vuong h, webster r, westby m, williams d.

author information: 
(1)discovery chemistry, sandwich laboratories, pfizer global research and
development, ramsgate road, kent, uk.

a major problem associated non-nucleoside reverse transcriptase inhibitors
(nnrtis) treatment hiv vulnerability mutations the
allosteric binding site reverse transcriptase result the
development resistant virus. herein present optimization series 
of 5-aryloxy imidazoles, possess balanced pharmacological profile against
both wild-type enzyme clinically relevant mutations k103n y181c.
subtle structural changes used probe structure-activity relationships
relating potency metabolic stability, led imidazole
derivative impressive overall profile.

doi: 10.1002/cmdc.200800183 
pmid: 18855969  [indexed medline]

